35 Trastuzumab for Sale
Trastuzumab
-
Price:
$100/Unit EXW
-
CAS No.:
180288-69-1
-
Grade:
Industrial Grade
-
Content:
99%
-
Packaging:
25kg/Cardboard Drum
Research Grade Trastuzumab
-
CAS No.:
180288-69-1
-
Grade:
Research Grade
-
Content:
95%
-
Packaging:
1mg
Trader | China
Main Products:
Antibody,Recombinant Protein,ELISA Kit
Certifications:
ISO 9001,IS0 13485
Trastuzumab (anti-HER2)
-
CAS No.:
180288-69-1
Trastuzumab Biosimilar
-
CAS No.:
180288-69-1
-
Grade:
research grade
-
Content:
95%
-
Packaging:
1mg, 5mg
Manufactory | United States
Main Products:
antibody,protein,primary cells,cancer cell lines,ELISA kits
Trastuzumab Deruxtecan
-
CAS No.:
1826843-81-5
Trader | China
Main Products:
Semaglutide,Tirzepatide,Retatrutide,Liraglutide,Orforgliprone Hemicalcium Hydrate
Certifications:
Business licence
About Trastuzumab List
- Buying Trastuzumab on www.echemi.com where you will find large variety of good choices. The suppliers of 35 Trastuzumab on the search result are been verified by the accurate information of each one. Accurate information is the prerequisite of transaction. We help you get chemicals in need continuously and meet registered Trastuzumab suppliers.
- We guarantee the quality of Trastuzumab 180288-69-1 on ECHEMI. Partners on ECHEMI are all selected in certification, qualification or scale. And we are familiar with the regulatory requirements from different areas of Trastuzumab. We can offer tailored service of Trastuzumab for our customers.
- Trastuzumab in reasonable and fair market price will be provided with better options and services. Member registered on ECHEMI will enjoy services of Trastuzumab for example market price and insights and trade data. Efficient order options is the key for supply chain services we offer for you. ECHEMI is helping you of Trastuzumab with global procurement service.
Check Out More Resources
- •Chinese Biopharmaceutical CompanyHenlius Expands to Middle East Market with Launch of Biosimilar Drug Trastuzumab®
- •Breakthrough in Metastatic Breast Cancer Treatment: Trastuzumab Deruxtecan Shows Impressive 13.2-Month mPFS
- •Revolutionary Breakthrough in Breast Cancer Treatment: Promising Results for Daiichi Sankyo/AstraZeneca's Trastuzumab Deruxtecan
- •DRL announces launch of trastuzumab biosimilar in India